Activity of tigecycline against levofloxacin-resistant pathogens from 2008
Abstract number: P1645
Hawser S., Johnson B., Bouchillon S., Badal R., Dowzicky M.
Background: Levofloxacin (LVX) is indicated for use in multiple therapeutic indications including urinary tract infections, skin and skin structure infections, pneumonia, sinusitis, pyelonephritis amnongst others. Resistance to this agent has risen since its introduction in clinical use and cross-resistance with other antibacterial classes has been reported. This report documents the activity of tigecycline and other antimicrobial agents against a range of LVX-resistant organisms isolated worldwide during 2008 as part of the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) study.
Methods: MICs were performed and interpreted according to CLSI and EUCAST / FDA guidelines where appropriate. A total of 32,468 clinical isolates were collected in this study of which 8,060 isolates (24.8%) exhibited resistance to LVX.
Results: The majority of LVX-resistant isolates were from Europe (48.6%), Latin America (24.5%) and North America (15.4%). The susceptibility of the most commonly detected LVX-resistant organisms for which tigecycline is indicated for use are shown in the table.
Conclusions: Taken together, this substantial body of data shows that LVX resistance is common though resistance to tigecycline was very low. There was no relationship between LVX-resistance and resistance to tigecycline. Tigecycline continues to exhibit excellent activity, including against isolates that are resistant to the widely used antibiotic LVX.
|Session name:||Abstracts 20th European Congress of Clinical Microbiology and Infectious Diseases|
|Location:||Vienna, Austria, 10 - 13 April 2010|
|Back to top|